All In Biotech

Drug Trial Radar · NCT06281236

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Feb 22, 2022

Primary completion

Mar 25, 2025

Study completion Apr 25, 2025

Sponsor

Lead sponsor
Sparrow PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be an open label phase 1b trial to characterize the pharmacodynamics and PK of prednisolone and SPI-62 when co-administered to participants with PMR. Up to 24 participants could be recruited.

Conditions

  • Polymyalgia Rheumatica

Interventions

  • PrednisoloneDrug

    Prednisolone according to the participant's pre-trial dose, symptoms and inflammatory biomarkers.

  • SPI-62Drug

    SPI-62 administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erythrocyte sedimentation rateTime frame: Baseline to Day 28
  2. C-reactive proteinTime frame: Baseline to Day 28
  3. Plasma fibrinogenTime frame: Baseline to Day 28

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Emovis Gmbh

    Berlin, Germany

  • Klinische Forschung Hannover Mitte GmbH/Pratia

    Hanover, Germany

  • Universitätsmedizin der Johannes Gutenburg Universität Mainz

    Mainz, Germany

  • Klinikum der Universität München

    München, Germany

  • Klinische Forschung Schwerin GmbH/Pratia

    Schwerin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.